Medlab Clinical is a medical research and development facility researching and formulating novel bio-therapeutics (e.g., nutraceuticals and pharmaceuticals) to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease and pre-diabetes/obesity.
Medlab Clinical - Research Focus
Focused research on biologics that target disease pathophysiological processes. Specifically, Medlab is investigating the role of bacteria in health and disease through perturbations of the gastrointestinal microbiome; and the ability of probiotic bacteria to modulate and beneficially impact end-organ physiology.
Medlab's current research portfolio covers:
MEDLAB'S PROBIOTIC GENERA
In order for Medlab to undertake research in the realm of novel therapeutics relevant to Chronic Diseases, Medlab has established intestinal cell lines (i.e., caco–2 / goblet cells combined) in a monolayer culture in an effort to undertake and investigate pro–inflammatory induced permeability studies and rescue with Medlab's premium probiotic species / strains.
Last updated 11th June 2019
After early years working in chartered accountants' offices, Michael joined Grace Brothers in their development phase and rose to be Head Office Controller. After eight years at Grace Brothers Michael left to have a short stint with Norman Ross (Harvey Norman) and then on to a private merchant bank. Michael became ill with cancer and his experience with that disease introduced him to the area of nutrition.
Michael has a long history in the management and building of successful nutritional companies. He sold Bioglan Limited to AusPharm Limited (1980s), built HealthComm USA with Dr Jeffrey Bland, relaunched VitaPlex Pty Ltd then sold to Health Minders Limited, built PharmaFoods Pty Ltd and sold it to FIT-BioCeuticals Limited.
Together with Sean Hall, Michael sold FIT-BioCeuticals Limited to Blackmores Limited in 2012.
Chief Executive Officer/Managing Director
Sean Hall founded Medlab in August 2012.
Sean has over 20 years experience in nutraceutical sales and development, as well as early drug discovery in Australia, Asia and the US. Sean has led and inspired his teams to author multiple patents, write peer reviewed articles and deliver lectures at scientific conferences. His passion is leading his researchers into novel areas and strong commercialisation opportunities.
Sean was a founder of FIT-BioCeuticals. Under his management and guidance BioCeuticals became the most innovative, research driven, practitioner brand in Australia. For his sale of FIT-BioCeuticals to Blackmores in 2012, Sean was a finalist in the inaugural Australian Exit CEO of the Year Award. Sean is a Board Member of the International Probiotics Association (IPA).
Drew is a senior partner in the chartered accounting firm Hall Chadwick and has been a partner in this firm for over 25 years. He is an experienced chartered accountant and corporate advisor to numerous SMEs.
Drew's industry and service specialisations include audits, prospectus preparation, expert reports, due diligence for takeovers and acquisitions and AFSL audits. In undertaking these roles Drew has developed extensive knowledge of ASIC and ASX requirements and regulations.
Drew's professional qualifications include Bachelor of Commerce (Accounting & Finance), Registered Auditor, Member of the Governance Institute, Member of the Australian Institute of Company Directors, Tax agent, Member of the Institute of Internal Auditors and Member of the Institute of Chartered Accountants.
Drew is an experienced director of both private and public companies and is currently chairperson of ASX listed Quantum Energy Ltd, a medical and energy technology company.
Last updated 11th June 2019